Biogen Inc. (NASDAQ:BIIB) saw a downside of -0.13% to close Friday at $261.15 after subtracting -$0.35 on the day. The 5-day average trading volume is 690,340 shares of the company’s common stock. It has gained $274.05 in the past week and touched a new high 1 time within the past 5 days. An average of 1,191,395 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,223,686.
BIIB’s 1-month performance is -4.93% or -$15.02 on its low of $256.13 reached on 07/28/23. The company’s shares have touched a 52-week low of $193.65 and high of $319.76, with the stock’s rally to the 52-week high happening on 06/12/23. YTD, BIIB has lost -5.69% or -$15.77 and has reached a new high 9 times. However, the current price is down -18.33% from the 52-week high price.
Insider Transactions
BIIB stock investors last saw insider trading activity on Jul 03.Singhal Priya (Head of Development) most recently sold 81 shares at $282.87 per share on Jul 03. This transaction cost the insider $22,912. EVP, Human Resources, Gregory Ginger, sold 2,681 shares at a price of $300.00 on Apr 28. Then, on Apr 04, Head of Development Singhal Priya sold 91 shares at a price of $277.11 per share. This transaction amounted to $25,217.
Valuation Metrics
BIIB stock has a beta of 0.14. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 3.80 while the price-to-book (PB) in the most recent quarter is 2.61, with the price to cash flow ratio at 33.72.
Biogen Inc.’s quick ratio for the period ended June 29 was 2.90, with the current ratio over the same period at 3.30. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.43, while the total debt to equity was 0.43. In terms of profitability, the gross margin trailing 12 months is 77.00%. The trailing 12-month EBITDA margin is 29.61% while for the period ending June 29, Biogen Inc.’s operating margin was 31.20%. The firm’s gross profit as reported stood at $7.9 billion against revenue of $10.17 billion.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -78.84% to $591.6 million, while revenue of $387.9 million was 34.43% off the previous quarter. Analysts expected BIIB to announce $3.77 per share in earnings in its latest quarter, but it posted $4.02, representing a 6.60% surprise. EBITDA for the quarter stood at more than $704.3 million. BIIB stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 10.7 billion, with total debt at $6.59 billion. Shareholders hold equity totaling $144.82 million.
Let’s look briefly at Biogen Inc. (BIIB) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 18 August was 31.25% to suggest the stock is trending Neutral, with historical volatility in this time period at 16.95%.
The stock’s 5-day moving average is $266.17, reflecting a -4.58% or -$12.53 change from its current price. BIIB is currently trading -5.63% above its 20-day SMA, -3.29% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -12.89% and SMA200 by-8.14%.
Stochastic %K and %D was 16.80% and 36.65% and the average true range (ATR) pointed at 5.65. The RSI (14) points at 34.53%, while the 14-day stochastic is at 7.27% with the period’s ATR at 5.88. The stock’s 9-day MACD Oscillator is pointing at -6.15 and -6.49 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Biogen Inc. (NASDAQ: BIIB), Scotiabank launched coverage with a Sector outperform rating. Analysts offering their rating for BIIB stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate BIIB as a “sell,”, while 9 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 3 rates the stock as overweight while 23 have offered a “buy” rating.
What is BIIB’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $269.00 and a high of $436.00, with their median price target at $329.00. Looking at these predictions, the average price target given by analysts is for Biogen Inc. (BIIB) stock is $326.42.
